Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand

  1. Home

  • Sunday, Nov 12th
    9:00 AM – 10:00 AM PT
    12S114: Pearls & Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis
    Location: Room 29A-D
    Moderator: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals
    Moderator: Abin Puravath, MD, FACP, MHS – Johns Hopkins University
    Moderator: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME: 1 hours
  • Sunday, Nov 12th
    9:00 AM – 9:15 AM PT
    Diagnostic Approach to Non-Radiographic Axial Spondyloarthritis
    Location: Room 29A-D
    Speaker: Mark Hwang, MD, MS – McGovern Medical School at the University of Texas Health Science Center at Houston
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:15 AM – 9:30 AM PT
    The Role of Imaging for Non-Radiographic Axial Spondyloarthritis
    Location: Room 29A-D
    Speaker: Lianne S. Gensler, MD – University of California San Francisco
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:30 AM – 9:45 AM PT
    Recognizing the Mimics of Axial Spondyloarthritis
    Location: Room 29A-D
    Speaker: Alexis Ogdie, MD – University of Pennsylvania
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:45 AM – 10:00 AM PT
    Q&A
    Location: Room 29A-D
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    (0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA
    Location: Poster Hall
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    (0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I: AxSpA
    Location: Poster Hall
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0482: Preference and Relative Sensitivity of Indicators Reporting Response Rate in Pharmaceutical Trials of Psoriasis and Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Jingru Tian, MD (she/her/hers) – Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0483: The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA)
    Location: Poster Hall
    Abstract Poster Presenter: Gary Macfarlane, MD, PhD, BSc, MBChB, DSc – University of Aberdeen
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0484: Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study
    Location: Poster Hall
    Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0485: Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial
    Location: Poster Hall
    Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0486: Identifying Serum Metabolomic Markers Associated with Psoriasis Skin Disease Activity
    Location: Poster Hall
    Abstract Poster Presenter: Vinod Chandran, MD, PhD, MBBS, DM, FRCPC – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0487: A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Ashmia Saif, DO (she/her/hers) – Stony Brook University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0488: Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity
    Location: Poster Hall
    Abstract Poster Presenter: Nancy Shadick, MD, MPH – Brigham & Women's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0489: Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study
    Location: Poster Hall
    Abstract Poster Presenter: Uta Kiltz, PhD – Rheumazentrum Ruhrgebiet
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0490: Racial/Ethnic Differences in Psoriatic Arthritis Patient Responses Regarding Disease Burden, Treatment, and Communication with Care Team
    Location: Poster Hall
    Abstract Poster Presenter: Marykate Nelson, PhD (she/her/hers) – PRIME Education
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0491: Arthralgia with Risk of Progression to Psoriatic Arthritis in a Large Cohort of Patients: Role of Ultrasound
    Location: Poster Hall
    Abstract Poster Presenter: Rodrigo Garcia Salinas, MD – Hospital Italiano La Plata
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0492: Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?
    Location: Poster Hall
    Abstract Poster Presenter: Rodrigo Garcia Salinas, MD – Hospital Italiano La Plata
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0493: Axial Disease Activity in Psoriatic Arthritis Is Higher in Patients with Carotid Plaque
    Location: Poster Hall
    Abstract Poster Presenter: Rosa Arvizu-Rivera, MD – Hospital Universitario \"Dr. José Eleuterio Gonzalez\"
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0494: Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque
    Location: Poster Hall
    Abstract Poster Presenter: Rosa Arvizu-Rivera, MD – Hospital Universitario \"Dr. José Eleuterio Gonzalez\"
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0495: Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study
    Location: Poster Hall
    Abstract Poster Presenter: Zulema Plaza, PhD, MSc – Fundacion Española de Reumatología
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0496: Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Valeria Gonzalez-Gonzalez, MD, MS (she/her/hers) – Universidad Autónoma de Nuevo León
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0497: Effects and Tolerability of Low to Moderate Biomechanical Stress During Leisure Sport Activity in Patients with Psoriasis and Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Axel Hueber, MD – Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University / Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0498: Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)
    Location: Poster Hall
    Abstract Poster Presenter: Howard Amital, MD – Sheba Medical Center, Tel-Hashomer, Israel
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0499: Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry
    Location: Poster Hall
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0500: Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention
    Location: Poster Hall
    Abstract Poster Presenter: Jose Federico Diaz-Gonzalez, MD – Hospital Universitario de Canarias
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0501: Multicentre Study of Uveitis in Spondyloarthritis: Prevalence, Characteristics, and Prognosis
    Location: Poster Hall
    Abstract Poster Presenter: Nikolaos Kougkas, MD, PhD (he/him/his) – 4th Internal Department, Ippokratio Hospital, Aristotle University of Thesaaloniki
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0502: Developing Electronic Health Record Algorithms to Accurately Identify Psoriatic Arthritis Patients
    Location: Poster Hall
    Abstract Poster Presenter: Avery Fortier, -None- – Vanderbilt University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0503: Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging
    Location: Poster Hall
    Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0504: Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature
    Location: Poster Hall
    Abstract Poster Presenter: Wilson Bautista-Molano, Sr, MD, PhD – University Hospital Fundación Santa Fe de Bogotá
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0505: Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study
    Location: Poster Hall
    Abstract Poster Presenter: M. Elaine Husni, MD, MPH – Cleveland Clinic
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0506: Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study
    Location: Poster Hall
    Abstract Poster Presenter: Avin Maroof, MD, DO, MSc, MBChB – University of Kurdistan Hawler
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0507: The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Antoni Chan, MD, PhD – Royal Berkshire NHS Foundation Trust
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0508: Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA
    Location: Poster Hall
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0509: Assessment of Direct and Indirect Impact on Pain and Fatigue Outcomes in a Phase 2 Clinical Trial of Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Active PsA: A Mediation Analysis
    Location: Poster Hall
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0510: Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
    Location: Poster Hall
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0511: Long-term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies
    Location: Poster Hall
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0512: Factors Associated with Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-year Follow-up of the DESIR Cohort
    Location: Poster Hall
    Abstract Poster Presenter: Elodie Portier, MD – Cochin Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0513: Impact of Pregnancy on Sacroiliac Imaging in Women with Axial Spondyloarthritis: Results of the Analysis of the DESIR Cohort
    Location: Poster Hall
    Abstract Poster Presenter: Elodie Portier, MD – Cochin Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0514: Difficult-to-treat Axial Spondyloarthritis Is Associated with Psoriasis and Comorbidities: Results from a Nationwide Study
    Location: Poster Hall
    Abstract Poster Presenter: Olivier Fakih, MD, MPH – CHU Besançon
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0515: Dose Adjustment of Tumor Necrosis Factor Inhibitors Does Not Correlated with Radiographic Progression in Patients with Ankylosing Spondylitis
    Location: Poster Hall
    Abstract Poster Presenter: Bon San Koo, MD – Inje University Seoul Paik Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0516: Drivers of Treatment Intensification in Patients with Axial Spondyloarthritis and High Disease Activity: Results from a Clinical Practice Registry
    Location: Poster Hall
    Abstract Poster Presenter: Rabab Nezam El-Din, BSc, MSc – Maastricht University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0517: Which ASDAS Cut-Off Corresponds Best to Treatment Intensification in Patients with Axial Spondyloarthritis in Daily Practice?
    Location: Poster Hall
    Abstract Poster Presenter: Rabab Nezam El-Din, BSc, MSc – Maastricht University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0518: Tofacitinib Efficacy and Safety in Patients with Ankylosing Spondylitis by Baseline C-Reactive Protein Levels: A Post Hoc Analysis
    Location: Poster Hall
    Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0519: Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and Its Open-Label Extension
    Location: Poster Hall
    Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0520: How Do Early Disease Activity and Early Clinical Response Associate with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis?
    Location: Poster Hall
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0521: Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
    Location: Poster Hall
    Abstract Poster Presenter: Martin Rudwaleit, MD – Klinikum Bielefeld Rosenhoehe, Bielefeld University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0522: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status
    Location: Poster Hall
    Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0523: Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
    Location: Poster Hall
    Abstract Poster Presenter: Victoria Navarro-Compán, MD – La Paz University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0524: Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Nigil Haroon, MD, PhD, DM, FRCPC, FRCP, MBA – University Health Network
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0525: Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
    Location: Poster Hall
    Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0526: Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
    Location: Poster Hall
    Abstract Poster Presenter: Maureen Dubreuil, MD, MSc – Boston University School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0527: Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
    Location: Poster Hall
    Abstract Poster Presenter: M. Elaine Husni, MD, MPH – Cleveland Clinic
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0528: Risk of Cardiovascular Disease Associated with Long-term Use of NSAIDs in Ankylosing Spondylitis
    Location: Poster Hall
    Abstract Poster Presenter: Seong-Kyu Kim, MD – Catholic University of Daegu School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0529: Sex-dependent Differences in Disease Characteristics Do Not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA)
    Location: Poster Hall
    Abstract Poster Presenter: Sabine Kugler – Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0530: Impact of Upadacitinib on Wearable Device-Measured Physical Activity in Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Trial
    Location: Poster Hall
    Abstract Poster Presenter: Jeffrey Curtis, MD, MS, MPH – University of Alabama at Birmingham
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0531: Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis
    Location: Poster Hall
    Abstract Poster Presenter: Bora Nam, MD – Hanyang University Hospital for Rheumatic Diseases
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0532: Factors Associated with Cause-specific Discontinuation of Long-term Anti-tumor Necrosis Factor Agent Use in Patients with Ankylosing Spondylitis
    Location: Poster Hall
    Abstract Poster Presenter: Bora Nam, MD – Hanyang University Hospital for Rheumatic Diseases
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0533: Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and b/tsDMARDs in Daily Practice?
    Location: Poster Hall
    Abstract Poster Presenter: Adrien NZEUSSEU TOUKAP, MD (he/him/his) – Cliniques universitaires Saint-Luc
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0534: Tapering Tofacitinib for Axial Spondyloarthritis in Remission or Low-disease Activity State
    Location: Poster Hall
    Abstract Poster Presenter: Pankti Mehta, MD, MBBS, DM – King George's Medical Univeristy
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0535: Pharmacologic Treatment of Ankylosing Spondylitis in a Large Urban Medical Center: Effects of Socioeconomic Status, Race/Ethnicity and Sex
    Location: Poster Hall
    Abstract Poster Presenter: Elizabeth Troy, BS – University of Illinois at Chicago
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0536: Asynchronous Tele Consultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy: Patients Perspective
    Location: Poster Hall
    Abstract Poster Presenter: Maria Rosa Exposito Molinero, MD – Hospital de Basurto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0537: Asynchronous Teleconsultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy as a More Sustainable Model Than Face-to-face Classical Consultation
    Location: Poster Hall
    Abstract Poster Presenter: Maria Rosa Exposito Molinero, MD – Hospital de Basurto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0538: The Challenge of Identifying Difficult-To-Treat Axial Spondyloarthritis in Clinical Practice: Results from La Paz-SpA Cohort
    Location: Poster Hall
    Abstract Poster Presenter: Manuel Juárez García, MD – Hospital Universitario La Paz
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0539: Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Maxime Dougados, MD – Université de Paris France
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0540: The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study
    Location: Poster Hall
    Abstract Poster Presenter: Angela Crowley, MD – Illinois Bone and Joint Institute - Hinsdale Orthopaedics
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0541: Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study
    Location: Poster Hall
    Abstract Poster Presenter: Prodromos Sidiropoulos, MD, PhD (he/him/his) – Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH)
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    9:00 AM – 11:00 AM PT
    0542: Two-Year Treatment Adherence and Clinical Response to Secukinumab Compared to TNF Inhibitors in Axial and Peripheral Spondyloarthritis Patients: A Single-Center Prospective Observational Study
    Location: Poster Hall
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    2:00 PM – 3:30 PM PT
    12S149: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: PsA (0775–0780)
    Location: Ballroom 20A
    Abstract Moderator: Jose Scher, MD – New York University School of Medicine
    Abstract Moderator: Enrique Soriano, MD, MSc – Hospital Italiano de Buenos Aires
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    2:00 PM – 2:10 PM PT
    0775: Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study
    Location: Ballroom 20A
    Presenting Author: Amy Peeters, BSc, MSc – Sint maartenskliniek
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    2:15 PM – 2:25 PM PT
    0776: Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study
    Location: Ballroom 20A
    Presenting Author: Alan J. Kivitz, MD – Altoona Center for Clinical Research
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    2:30 PM – 2:40 PM PT
    0777: Characteristics of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis
    Location: Ballroom 20A
    Presenting Author: Cecile PHILIPPOTEAUX, MD, PharmD, MSc – University Hospital Center of Lille
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    2:45 PM – 2:55 PM PT
    0778: The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis - A Randomized Controlled Trial
    Location: Ballroom 20A
    Presenting Author: Martin Stradner, MD – Medical University of Graz
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    3:00 PM – 3:10 PM PT
    0779: Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)
    Location: Ballroom 20A
    Presenting Author: Laura PINA VEGAS, MD, PhD – Henri Mondor University Hospital (APHP), Rheumatology Department
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    3:15 PM – 3:25 PM PT
    0780: Assessing Differential Effects of DMARDs on Psoriasis Area and Severity Index and Patient Global Assessment in Subgroups of Patients with Active PsA Treated over 52-weeks with Secukinumab in a Non-Interventional Trial (AQUILA) Using a Multistage Clustering Approach
    Location: Ballroom 20A
    Presenting Author: Sina Mackay, MSc – Fraunhofer-Institut für Intelligente Analyse- und Informationssysteme IAIS
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    4:00 PM – 5:30 PM PT
    12S168: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: AxSpA (0841–0846)
    Location: Ballroom 20A
    Abstract Moderator: Jonathan Chan, MD, BSc, FRCPC – UBC
    Abstract Moderator: Mark Hwang, MD, MS – McGovern Medical School at the University of Texas Health Science Center at Houston
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    4:00 PM – 4:10 PM PT
    0841: Spondyloarthritis Research and Treatment Network (SPARTAN) Draft Referral Recommendations for Axial Spondyloarthritis
    Location: Ballroom 20A
    Presenting Author: Maureen Dubreuil, MD, MSc – Boston University School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    4:15 PM – 4:25 PM PT
    0842: Low Rate of Switching from Nr-axSpA to r-axSpA After 10 Years of Follow up in Early Axialspondyloarthritis. Data from DESIR Cohort
    Location: Ballroom 20A
    Presenting Author: Anna Molto, MD, PhD (she/her/hers) – Assistance Publique Hôpitaux de Paris
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    4:30 PM – 4:40 PM PT
    0843: Predictive Validity of Data-driven Definitions for Active and Structural Lesions in the SI Joints Typical for Axial SpA: A 2-year Follow-up in the SPondyloArthritis Caught Early Cohort
    Location: Ballroom 20A
    Presenting Author: Sofia Ramiro, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    4:45 PM – 4:55 PM PT
    0844: Facet Joint Inflammation Is Rare, but When Present It Is Associated with Facet Joint Ankylosis in Radiographic Axial Spondyloarthritis Patients from the SIAS Cohort
    Location: Ballroom 20A
    Presenting Author: Manouk de Hooge, PhD – Ghent University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    5:00 PM – 5:10 PM PT
    0845: The Yield of Repeated Assessments in Chronic Back Pain Patients Suspected of Early Axial Spondyloarthritis: Two-year Data from the SPondyloArthritis Caught Early (SPACE) Cohort
    Location: Ballroom 20A
    Presenting Author: Mary Lucy Marques, MD, MSc – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 12th
    5:15 PM – 5:25 PM PT
    0846: Preosteoclast Plays a Pathogenic Role in Syndesmophyte Formation of Ankylosing Spondylitis Through the Secreted PDGFB - GRB2/ERK/RUNX2 Pathway
    Location: Ballroom 20A
    Presenting Author: Yulong Tang, PhD – Fudan University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    (1383–1411) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Imaging & AS
    Location: Poster Hall
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    (1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA
    Location: Poster Hall
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1384: Functional Status by Sex and Socioeconomic Status in Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Rachael Stovall, MD (she/her/hers) – University of Washington
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1385: Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice - Results of an Online Survey Amongst Rheumatology Care Providers
    Location: Poster Hall
    Abstract Poster Presenter: Joerg Ermann, MD – Brigham and Women's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1386: Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis
    Location: Poster Hall
    Abstract Poster Presenter: Berk Degirmenci, MD – Boston University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1387: Power Doppler Musculoskeletal Abnormalities in Patients with Psoriasis at High Risk of Progression to Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Rebecca Haberman, MD – NYU Langone Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1388: Pain Mechanisms in Psoriatic Arthritis: Differentiating Inflammation Related Pain in Enthesitis Using Ultrasound, in Comparison to Functional MRI
    Location: Poster Hall
    Abstract Poster Presenter: Ummugulsum Gazel, MD – University of Ottawa
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1389: Low Spinal Radiographic Progression After a Mean of 15 Years of Follow-up in a Cohort of Patients with Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Raquel Granados, MD – Hospital Universitario Reina Sofia
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1390: Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study
    Location: Poster Hall
    Abstract Poster Presenter: Uta Kiltz, PhD – Rheumazentrum Ruhrgebiet
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1391: Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care
    Location: Poster Hall
    Abstract Poster Presenter: Uta Kiltz, PhD – Rheumazentrum Ruhrgebiet
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1392: Improving the Diagnostic Accuracy in Axial Spondyloarthritis: Interim Results of a Nationwide Telemedicine Project
    Location: Poster Hall
    Abstract Poster Presenter: Denis Poddubnyy, MD, PhD, MSc – Charité-Universitätsmedizin Berlin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1393: Fully Automated Detection of Active Sacroiliitis in Patients with Axial Spondyloarthritis: A Machine Learning-Based Analysis Magnetic Resonance Image
    Location: Poster Hall
    Abstract Poster Presenter: Sang Tae Choi, MD, PhD – Chung-Ang University College of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1394: Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study
    Location: Poster Hall
    Abstract Poster Presenter: Bon San Koo, MD – Inje University Seoul Paik Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1395: Aerobic Capacity and Its Relation to Disease Characteristics and Lifestyle Habits in Patients with Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Elisabeth Mogard, PhD, PT – Skåne University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1396: Comprehensive Evaluation of the Digital Annular Pulleys: From Ultrasonographical to Anatomical and Histological Evaluation with Special Focus on the Entheses
    Location: Poster Hall
    Abstract Poster Presenter: Luis Coronel, Sr, -None- – Hospital Universitari Vall d´Hebron
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1397: Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
    Location: Poster Hall
    Abstract Poster Presenter: Victoria Navarro-Compán, MD – La Paz University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1398: A Deep Learning Algorithm for MRI Spinal Inflammation in Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Chiu Wai Shirley Chan, MBBS – Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1399: Trends in Proportionate Cardiovascular Mortality in Patients with Ankylosing Spondylitis in the Era of Biologic Therapies: Analysis of US Death Certificate Data
    Location: Poster Hall
    Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1400: Achieving ASDAS Inactive Disease Status in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
    Location: Poster Hall
    Abstract Poster Presenter: Sarah Abi Doumeth, MD – Case Western Reserve University/University Hospitals Cleveland Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1401: The Association of 3VAS/4VAS and DAPSA with Radiographic Progression in Early PsA
    Location: Poster Hall
    Abstract Poster Presenter: Marinus Vis, MD – Erasmus MC
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1402: Exceeding Activity Targets but Missing the Mark with Sleep: Mapping 24-Hour Movement Guidelines in Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Laura Passalent, BSc, PT, MHS – Schroeder Arthritis Institute, University Health Network
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1403: MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients
    Location: Poster Hall
    Abstract Poster Presenter: Kristyna Bubova, PhD – Institute of Rheumatology and Department of Rheumaotlogy, First Faculty of Medicine, Prague
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1404: Factor H-related protein-5 Exacerbates Pathological Bone Formation of Ankylosing Spondylitis
    Location: Poster Hall
    Abstract Poster Presenter: Chang-Nam Son, MD, PhD – UIJEONGBU EULJI MEDICAL CENTER, EULJI UNIVERSITY
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1405: Diagnostic Delay of Axial Spondyloarthritis in African American Patients
    Location: Poster Hall
    Abstract Poster Presenter: John Byun, MD – 219 Health Network
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1406: Temporal Trends in Cardiovascular Events in Axial Spondyloarthritis Patients with Medicare Insurance versus Commercial Insurance: An Analysis Using Claims Data
    Location: Poster Hall
    Abstract Poster Presenter: Rouhin Sen, MD, MS – University of Alabama Birmingham
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1407: Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA
    Location: Poster Hall
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1408: Impact of Disease Activity on Functional Impairment in Patients with Spondyloarthritis Is Different According to the Degree of Radiographic Progression: Result from SNUH-AS Cohort
    Location: Poster Hall
    Abstract Poster Presenter: Ji In Jung, MD – Seoul National University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1409: Analysis of Soluble Biomarkers in Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Caroline Bauchiero, MS (she/her/hers) – Brigham and Women's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1410: The Use of the ASAS Referral Criteria Together with Increased Education and Training of Its Use Improves Delay to Diagnosis of Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Antoni Chan, MD, PhD – Royal Berkshire NHS Foundation Trust
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1411: Prevalence of Early Axial Spondyloarthritis in the Be-GIANT Cohort Based on the ASAS Consensus Definition of Early Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Gaëlle Varkas, MD, PhD (she/her/hers) – Ghent University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1412: Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
    Location: Poster Hall
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1413: Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST
    Location: Poster Hall
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1414: Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1415: Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD‑Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
    Location: Poster Hall
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1416: Improvement of Work Absenteeism Following Start of Methotrexate Monotherapy in Newly-Diagnosed Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Johan Karlsson Wallman, MD, PhD – Lund University and Skane University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1417: Do Long-term Patient-reported Outcomes Improve Similarly in Psoriatic Arthritis and Axial Spondyloarthritis Patients Treated with Secukinumab? Results from the EuroSpA Collaboration
    Location: Poster Hall
    Abstract Poster Presenter: Marion Pons, MD – Rigshospitalet, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark.
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1418: Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial
    Location: Poster Hall
    Abstract Poster Presenter: Miroslawa Nowak, MD – Bristol Myers Squibb
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1419: Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab
    Location: Poster Hall
    Abstract Poster Presenter: Peter Nash, FRACP – Griffith UNiversity
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1420: Changes in Serum Cytokines and Collagen Proteins Correlate with Durability of Guselkumab Efficacy and Continued Disease Improvement Through 2 Years in Patients with Active Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Proton Rahman, MD – Memorial University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1421: Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS)
    Location: Poster Hall
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1422: Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data
    Location: Poster Hall
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1423: Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial
    Location: Poster Hall
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1424: Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients
    Location: Poster Hall
    Abstract Poster Presenter: Dafna Gladman, MD, FRCPC – University of Toronto, Toronto Western Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1425: Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis
    Location: Poster Hall
    Abstract Poster Presenter: Dafna Gladman, MD, FRCPC – University of Toronto, Toronto Western Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1426: Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib
    Location: Poster Hall
    Abstract Poster Presenter: Dafna Gladman, MD, FRCPC – University of Toronto, Toronto Western Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1427: Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials
    Location: Poster Hall
    Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1428: Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
    Location: Poster Hall
    Abstract Poster Presenter: Laure Gossec, MD, PhD – Sorbonne Universite
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1429: Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
    Location: Poster Hall
    Abstract Poster Presenter: Carlo Selmi, MD, PhD – Humanitas University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1430: A Proof-of-concept Study Evaluating the Use of Functional Brain Magnetic Resonance Imaging in Assessing Treatment Response in Psoriatic Arthritis Patients
    Location: Poster Hall
    Abstract Poster Presenter: Esther Espartal Lopez, MD – Vall Hebron Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1431: Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results
    Location: Poster Hall
    Abstract Poster Presenter: Peter Taylor, PhD, FRCP, MA – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1432: Experiences and Perspectives of Patients with Psoriatic Arthritis Participating in a Randomized Controlled Trial of Dietary Interventions
    Location: Poster Hall
    Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1433: Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
    Location: Poster Hall
    Abstract Poster Presenter: Joseph Merola, MD, MSc – Harvard Medical School, Brigham and Women's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1434: Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
    Location: Poster Hall
    Abstract Poster Presenter: Filip Van den Bosch, MD, PhD – Ghent University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1435: Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial
    Location: Poster Hall
    Abstract Poster Presenter: Frank Behrens, MD, PhD – Goethe-University & Fraunhofer ITMP
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1437: Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study
    Location: Poster Hall
    Abstract Poster Presenter: Christopher Ritchlin, MD, MPH – University of Rochester Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1438: Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active PsA
    Location: Poster Hall
    Abstract Poster Presenter: Enrique Soriano, MD, MSc – Hospital Italiano de Buenos Aires
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1439: Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA
    Location: Poster Hall
    Abstract Poster Presenter: Jakub Závada, MD, PhD – Institute of Rheumatology, Prague
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1440: Removal of Methotrexate in Patients with Active Psoriatic Arthritis with Newly Induced Ustekinumab Treatment Leads to a Delayed Response in DAPSA and DAS28 Within the First 16 Weeks
    Location: Poster Hall
    Abstract Poster Presenter: Michaela Koehm, MD (she/her/hers) – University Hospital Frankfurt
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    9:00 AM – 11:00 AM PT
    1441: Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial
    Location: Poster Hall
    Abstract Poster Presenter: Joseph Merola, MD, MSc – Harvard Medical School, Brigham and Women's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    2:00 PM – 3:30 PM PT
    13M151: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Psoriatic Arthritis (1639–1644)
    Location: Ballroom 20A
    Abstract Moderator: Paras Karmacharya, MD, MS – Vanderbilt University, Nashville, TN
    Abstract Moderator: Evan Siegel, MD – Arthritis and Rheumatism Associates/Georgetown University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    2:00 PM – 2:10 PM PT
    1639: PsA Patients of Diverse Ethnic and Racial Backgrounds Experience More Skin Psoriasis, Increased Pain, and Higher Rates of Radiographic Axial Disease
    Location: Ballroom 20A
    Presenting Author: Rebecca Haberman, MD – NYU Langone Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    2:15 PM – 2:25 PM PT
    1640: Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network
    Location: Ballroom 20A
    Presenting Author: Rebecca Haberman, MD – NYU Langone Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    2:30 PM – 2:40 PM PT
    1641: The Window of Opportunity in Psoriatic Arthritis: Similar to Rheumatoid Arthritis?
    Location: Ballroom 20A
    Presenting Author: Marinus Vis, MD – Erasmus MC
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    2:45 PM – 2:55 PM PT
    1642: Identifying Distinct Phenotypes in Psoriatic Arthritis: A Study from the Psoriatic Arthritis Research Consortium (PARC) Cohort
    Location: Ballroom 20A
    Presenting Author: Paras Karmacharya, MD, MS – Vanderbilt University, Nashville, TN
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    3:00 PM – 3:10 PM PT
    1643: Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis
    Location: Ballroom 20A
    Presenting Author: Vinod Chandran, MD, PhD, MBBS, DM, FRCPC – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    3:15 PM – 3:25 PM PT
    1644: The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients
    Location: Ballroom 20A
    Presenting Author: Alba Boix-Amoros, PhD – Icahn School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    4:00 PM – 5:30 PM PT
    13M167: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA (1687–1692)
    Location: Ballroom 20A
    Abstract Moderator: Uta Kiltz, PhD – Rheumazentrum Ruhrgebiet
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    4:00 PM – 4:10 PM PT
    1687: Sex of the Patient Affects Response to Advanced Therapies in Psoriatic Arthritis: Meta-analysis of Data from Randomized Controlled Trials
    Location: Ballroom 20A
    Presenting Author: Lihi Eder, MD, PhD – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    4:15 PM – 4:25 PM PT
    1688: Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks
    Location: Ballroom 20A
    Presenting Author: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    4:30 PM – 4:40 PM PT
    1689: Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy
    Location: Ballroom 20A
    Presenting Author: Lihi Eder, MD, PhD – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    4:45 PM – 4:55 PM PT
    1690: Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
    Location: Ballroom 20A
    Presenting Author: Mikkel Østergaard, MD, PhD, DMSc – Rigshospitalet, University of Copenhagen
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    5:00 PM – 5:10 PM PT
    1691: 16-Week Results from FOREMOST, a Placebo-Controlled Study Involving Oligoarticular Psoriatic Arthritis Treated with Apremilast
    Location: Ballroom 20A
    Presenting Author: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 13th
    5:15 PM – 5:25 PM PT
    1692: Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)
    Location: Ballroom 20A
    Presenting Author: Axel Finckh, MD – HUG
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 10:00 AM PT
    14T121: Spondyloarthropathy: Comparing Adult and Pediatric Diseases
    Location: Room 7A-B
    Moderator: Robert Colbert, MD, PhD – NIH/NIAMS
    Moderator: Shirley Tse, MD, FRCPC – SickKids
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME: 1 hours
  • Tuesday, Nov 14th
    9:00 AM – 9:15 AM PT
    Classification of Early Axial Disease in Spondyloarthritis
    Location: Room 7A-B
    Speaker: Pamela Weiss, MD – Childrens Hospital of Philadelphia
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:15 AM – 9:30 AM PT
    Magnetic Resonance Imaging Evidence of Inflammation and Structural Lesions: Adults Versus Children
    Location: Room 7A-B
    Speaker: Walter P. Maksymowych, MD – University of Alberta
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:30 AM – 9:45 AM PT
    Updates and Differences in Management
    Location: Room 7A-B
    Speaker: Hemalatha Srinivasalu, MD, MBBS – Children's National Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:45 AM – 10:00 AM PT
    Q&A
    Location: Room 7A-B
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    (1776–1795) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster
    Location: Poster Hall
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    (2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA
    Location: Poster Hall
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    (2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III: SpA
    Location: Poster Hall
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    L11: Risk of Cardiovascular Events According to Biological Agent Exposure in Patients with Ankylosing Spondylitis: A Korean Population-based Study
    Location: Poster Hall
    Late-Breaking Poster Presenter: Oh Chan Kwon, MD, PhD (he/him/his) – Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    L12: Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
    Location: Poster Hall
    Late-Breaking Poster Presenter: Alan J. Kivitz, MD – Altoona Center for Clinical Research
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1776: Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression
    Location: Poster Hall
    Abstract Poster Presenter: Shaghayegh Foroozan, MSc (she/her/hers) – University Health Network/University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1777: The Effect of the Inflamed Joint Microenvironment on Endothelial Cell Function
    Location: Poster Hall
    Abstract Poster Presenter: Aenea Brugman, BSc, MSc (she/her/hers) – Trinity College Dublin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1778: Role of GITR/GITRL Interaction in Modulating T Helper 9, T Helper 17 and T Regulatory Response in Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Chiara Rizzo, MD – University of Palermo
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1779: A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation
    Location: Poster Hall
    Abstract Poster Presenter: Smadar Gertel, PhD (she/her/hers) – Tel-Aviv Sourasky Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1780: Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study
    Location: Poster Hall
    Abstract Poster Presenter: Jiri Baloun, PhD – Institute of Rheumatology
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1781: TNF Induces Neutrophil Elastase/Gasdermin D-mediated Neutrophil Extracellular Traps in Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Yehao Li, PhD – The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, China
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1782: The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
    Location: Poster Hall
    Abstract Poster Presenter: Jia (Sijia) Chen, MD, PhD – Brigham and Women's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1783: Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis
    Location: Poster Hall
    Abstract Poster Presenter: Marcos Chinas Hernandez, Sr, BSc – Boston Children's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1784: Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model
    Location: Poster Hall
    Abstract Poster Presenter: Unnikrishnan Chandrasekharan, PhD – Cleveland Clinic
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1785: Machine Learning Models Identify Gut Microbiota That Predict Chronicity in Reactive Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Prakashini MV, MD (she/her/hers) – Kalinga Institute of Medical Sciences, KIIT University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1786: Newly Identified Gut Commensal Clostridium Fessum AM100 for Treating Ankylosing Spondylitis
    Location: Poster Hall
    Abstract Poster Presenter: Lu Bai, PhD – Fudan University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1787: Regulatory Role of JAK-1/TYK2 Signaling on the Pannus Formation: Novel Mechanisms for JAK Inhibitors in Psoriatic Disease
    Location: Poster Hall
    Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1788: The Emerging Mechanism of TNF&IL-17A/WNT5a/ROR2 Axis in Pathological Bone Formation of Ankylosing Spondylitis
    Location: Poster Hall
    Abstract Poster Presenter: Sungsin Jo, PhD – Hanyang Univerisity Institue for Rheumatology Research
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1789: Microtrauma Exacerbates Arthritis and Enthesitis in Curdlan-administered SKG Mice by Inducing FGF16 Expresssion
    Location: Poster Hall
    Abstract Poster Presenter: Seung Hoon Lee, PhD – Hanyang University Institute for Rheumatology Research
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1790: Expansion of CD8+ TCRVβ9+ T Cells in the Peripheral Blood of HLA-B27+ Patients with Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Caroline Bauchiero, MS (she/her/hers) – Brigham and Women's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1791: Exploring the Mechanism of Anti-TNFα Therapy Non-response in Psoriatic Arthritis: The Role of TNF Receptor 2 Polymorphisms rs1061622
    Location: Poster Hall
    Abstract Poster Presenter: James Sullivan, BA (he/him/his) – Cleveland Clinic Lerner College of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1792: Identifying Synovial Fluid Micro-RNA Signature That Distinguishes Psoriatic Arthritis from Osteoarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Darshini Ganatra, PhD – University Health Network
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1793: Goblet Cell Specific Anti-Apoptotic Role of Interleukin-24 in Spondyloarthritis-Associated Ileitis
    Location: Poster Hall
    Abstract Poster Presenter: Amy Cameron, BSc – Frazer Institute, The University of Queensland
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1794: The Role of the Deubiquitinase ZRANB1/TRABID in Inflammation and Bone Formation in Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Archita Srinath, BSc, MSc (she/her/hers) – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    1795: Multi-Omics Analyses Identify Metabolic Pathways That Differentiate Psoriatic Arthritis from Psoriasis
    Location: Poster Hall
    Abstract Poster Presenter: Vinod Chandran, MD, PhD, MBBS, DM, FRCPC – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2195: Regional Differences in Clinical Phenotype of Axial Spondyloarthritis. Results from the International Map of Axial Spondyloarthritis (IMAS)
    Location: Poster Hall
    Abstract Poster Presenter: Denis Poddubnyy, MD, PhD, MSc – Charité-Universitätsmedizin Berlin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2196: Females with Axial Spondyloarthritis Report Higher Burden of Disease and Worse Patient-reported Outcomes. Results from the International Map of Axial Spondyloarthritis (IMAS)
    Location: Poster Hall
    Abstract Poster Presenter: Victoria Navarro-Compán, MD – La Paz University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2197: Diagnostic Delay in Patients Included in the International Map of Axial Spondyloarthrtis: Associations with Geographic, Socio-demographic and Disease-related Factors
    Location: Poster Hall
    Abstract Poster Presenter: Denis Poddubnyy, MD, PhD, MSc – Charité-Universitätsmedizin Berlin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2198: Which Factors Are Associated with Clinically High Disease Activity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)
    Location: Poster Hall
    Abstract Poster Presenter: Victoria Navarro-Compán, MD – La Paz University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2199: Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration
    Location: Poster Hall
    Abstract Poster Presenter: Marion Pons, MD – Rigshospitalet, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark.
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2200: Sensitivity to Change of Structural Outcomes in Early Axial Spondyloarthritis After 10 Years of Follow Up. Data from DESIR Cohort
    Location: Poster Hall
    Abstract Poster Presenter: Clementina Lopez-Medina, MD – Reina Sofia University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2201: When Usual Care Is Not so Usual: Facing the Challenges of Protocol Violations and Generalisability When Running a Strategy Trial. the Example of the Cluster-Randomized TICOSPA Trial
    Location: Poster Hall
    Abstract Poster Presenter: Clementina Lopez-Medina, MD – Reina Sofia University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2202: Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Moderate to Severe Psoriasis: Long-Term Efficacy in Placebo Crossovers
    Location: Poster Hall
    Abstract Poster Presenter: Andrew Napoli, PhD – Bristol Myers Squibb
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2203: Self-Reported and Physician´s Assessment of Inflammatory Back Pain According to ASAS Criteria: Is It the Same?
    Location: Poster Hall
    Abstract Poster Presenter: Diego Benavent, MD – Hospital Universitario de Bellvitge
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2204: Residual Disease Activity in Canadian Patients with Axial Spondyloarthritis: Results from a Multi-registry Analysis (UNISON-Axial SpA)
    Location: Poster Hall
    Abstract Poster Presenter: Walter P. Maksymowych, MD – University of Alberta
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2205: Disease Activity and Widespread Pain Are the 2 Key Drivers of Global Health in Axial Spondyloarthritis, with Similar Findings in Different Patient Populations: An Analysis of 4 Databases and 6064 Patients
    Location: Poster Hall
    Abstract Poster Presenter: Juliette Drouet, MD – Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2206: Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: ERIC TOUSSIROT, MD, PhD (he/him/his) – university hospital of BESANCON
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2207: Knowledge, Awareness, and Attitudes Regarding Inflammatory Back Pain Among Non-Rheumatology Physicians in the United States
    Location: Poster Hall
    Abstract Poster Presenter: William Odell, BS – Yale University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2208: Awareness and Attitudes Regarding Axial Spondyloarthritis Among Non-Rheumatology Physicians in the United States
    Location: Poster Hall
    Abstract Poster Presenter: William Odell, BS – Yale University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2209: Prevalence and Clinical Characteristics of Late Onset Axial Spondyloarthritis: Results from a Multicentre Nationwide Study
    Location: Poster Hall
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2210: Antibodies to Four Novel Peptides in New Onset Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Pieter Ruytinx, PhD – Hasselt University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2211: A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort
    Location: Poster Hall
    Abstract Poster Presenter: Ana Bento da Silva, MD – Centro Hospitalar de Lisboa Ocidental
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2212: Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2213: Identification of a Diagnostic Model for Axial Spondyloarthritis in Daily Clinical Practice Using a Random Forest Machine Learning Approach
    Location: Poster Hall
    Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2214: Systematic Literature Review and Meta-analysis Informing the Development of 2023 Spondyloarthritis Research and Treatment Network (SPARTAN) Referral Recommendations for Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Abhijeet Danve, MD, MHS – Yale University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2215: Can Axial Spondyloarthritis Unequivocally Be Diagnosed by Rheumatologists in Patients with Chronic Back Pain of Less Than Two Years Duration? The Primary Outcome of the Two-year SPondyloArthritis Caught Early (SPACE) Cohort
    Location: Poster Hall
    Abstract Poster Presenter: Mary Lucy Marques, MD, MSc – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2216: WITHDRAWN
    Location: Poster Hall
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2217: Gender Disparities in Disease Activity Scores and Treatment Response Among Patients with Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Seulkee Lee, MD, PhD (he/him/his) – Samsung Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2218: Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients
    Location: Poster Hall
    Abstract Poster Presenter: Vinod Chandran, MD, PhD, MBBS, DM, FRCPC – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2219: Comparing the Construct Validity Among Measures of Pain and Stiffness in Patients with Axial Spondyloarthritis
    Location: Poster Hall
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2220: Factors Associated with Achieving Remission in Patients with Early Peripheral Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort
    Location: Poster Hall
    Abstract Poster Presenter: Denis Poddubnyy, MD, PhD, MSc – Charité-Universitätsmedizin Berlin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2221: Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers
    Location: Poster Hall
    Abstract Poster Presenter: Maria Angeles Puche Larrubia, MD, PhD – Reina Sofia University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2222: Association Spondyloarthritis and Inflammatory Bowel Disease, More Severe Diseases on Both Sides
    Location: Poster Hall
    Abstract Poster Presenter: Juliane Michel, -None- – Université de Bourgogne Franche-Comté
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2223: Relationship Between Sleep Quality, Disease Activity, and Psychological Factors in Patients with Axial Spondyloarthritis: A Cross Sectional Study
    Location: Poster Hall
    Abstract Poster Presenter: Srujana Budumuru, MD – Indraprastha Apollo Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2225: Long-term Evolution of Spondyloarthritis Patients Included in REGISPONSER, 17 Years Later (REGISPON-3 Study)
    Location: Poster Hall
    Abstract Poster Presenter: Maria Angeles Puche Larrubia, MD, PhD – Reina Sofia University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2226: How Do Spondyloarthritis Start? Identification of the First Signs or Symptoms According to Diagnosis and HLA-B27. Data from REGISPONSER and RESPONDIA Registries
    Location: Poster Hall
    Abstract Poster Presenter: Maria Angeles Puche Larrubia, MD, PhD – Reina Sofia University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2227: The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration
    Location: Poster Hall
    Abstract Poster Presenter: Zohra Faizy Ahmadzay, MD – University of Copenhagen, COPECARE
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2228: Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment
    Location: Poster Hall
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2229: Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies
    Location: Poster Hall
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2230: Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year
    Location: Poster Hall
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2231: Ixekizumab Significantly Improves Nail Disease and Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Dennis McGonagle, MD, PhD – Uni of Leeds
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2232: Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23
    Location: Poster Hall
    Abstract Poster Presenter: Dennis McGonagle, MD, PhD – Uni of Leeds
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2233: Neutrophil Levels Associate with Early Improvement in Spinal Pain and Week 24 Multi-Domain Disease Control During Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials
    Location: Poster Hall
    Abstract Poster Presenter: Dennis McGonagle, MD, PhD – Uni of Leeds
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2234: Disagreement Between Patient and Physician Global Assessment over Time in Psoriatic Arthritis: Insight into Treatment Priorities
    Location: Poster Hall
    Abstract Poster Presenter: Proton Rahman, MD – Memorial University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2235: Identifying Differentially Expressed Genes to Predict TNF-Alpha and IL-17A Inhibitor Response in Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Proton Rahman, MD – Memorial University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2236: Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Jeffrey Curtis, MD, MS, MPH – University of Alabama at Birmingham
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2237: Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice
    Location: Poster Hall
    Abstract Poster Presenter: Irati Urionaguena – OSAKIDETZA
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2238: Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
    Location: Poster Hall
    Abstract Poster Presenter: Arthur Kavanaugh, MD – UCSD
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2239: Achievement of Disease Control in PsA Patients Treated with Upadacitinib at Week 152: Post Hoc Analysis of the Long-term Extensions of Two Phase 3 Trials
    Location: Poster Hall
    Abstract Poster Presenter: Arthur Kavanaugh, MD – UCSD
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2240: Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)
    Location: Poster Hall
    Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2241: Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
    Location: Poster Hall
    Abstract Poster Presenter: Renaud FELTEN, MD, PhD – Hopitaux Universitaires de Strasbourg
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2242: Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes
    Location: Poster Hall
    Abstract Poster Presenter: M. Elaine Husni, MD, MPH – Cleveland Clinic
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2243: Ultrasound Enthesitis Responsiveness versus Clinical Enthesitis Responsiveness: Week 52 Results of an Exploratory Analysis from a Phase 3b Study in Patients with Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Maria Antonietta D'Agostino, MD, PhD – Università Cattolica del Sacro Cuore
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2244: Switching Between Biologics and Targeted Synthetic Therapies Due to Inefficacy in Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Dalifer Freites Nuñez, MD – Hospital Clínico San Carlos. Madrid. Spain.
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2245: Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients with PsA in the Multicountry Postmarketing Observational VALUE Study
    Location: Poster Hall
    Abstract Poster Presenter: Ralph Lippe, PhD – AbbVie
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2246: Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan
    Location: Poster Hall
    Abstract Poster Presenter: mitsumasa kishimoto, MD – Kyorin University School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2247: Gender Differences in Switching Biological and Targeted Synthetic Therapies in Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Leticia Leon, PhD, MSc (she/her/hers) – Hospital Clinico San Carlos
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2248: Primary Non-response in Psoriatic Arthritis Treated with Biologics and Targeted Synthetic Therapies in Daily Clinical Practice
    Location: Poster Hall
    Abstract Poster Presenter: lydia Abasolo Alcazar – IdISSC. HCSC
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2249: Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
    Location: Poster Hall
    Abstract Poster Presenter: Dafna Gladman, MD, FRCPC – University of Toronto, Toronto Western Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2250: Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
    Location: Poster Hall
    Abstract Poster Presenter: Dafna Gladman, MD, FRCPC – University of Toronto, Toronto Western Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2251: Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study
    Location: Poster Hall
    Abstract Poster Presenter: Peter Taylor, PhD, FRCP, MA – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2252: Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
    Location: Poster Hall
    Abstract Poster Presenter: Christopher Ritchlin, MD, MPH – University of Rochester Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2253: Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast
    Location: Poster Hall
    Abstract Poster Presenter: Joseph Merola, MD, MSc – Harvard Medical School, Brigham and Women's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2254: The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Location: Poster Hall
    Abstract Poster Presenter: Ruoning (Lemon) Ni, MD (she/her/hers) – University of Iowa Hospitals and Clinics
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2255: Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
    Location: Poster Hall
    Abstract Poster Presenter: Joseph Merola, MD, MSc – Harvard Medical School, Brigham and Women's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2256: The Impact of Clinical Trial Metrics in Psoriatic Arthritis
    Location: Poster Hall
    Abstract Poster Presenter: Kara Murray, BS – Spherix Global Insights
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    9:00 AM – 11:00 AM PT
    2241.5: Long-term Retention of Secukinumab and Effect of Treatment Interruption in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis: Results from the Observational SERENA Study
    Location: Poster Hall
    Abstract Poster Presenter: Uta Kiltz, PhD – Rheumazentrum Ruhrgebiet
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    2:00 PM – 3:30 PM PT
    14T159: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (2437–2442)
    Location: Room 30D-E
    Abstract Moderator: Iannis Adamopoulos, PhD – Harvard Medical School, BIDMC, Division of Rheumatology
    Abstract Moderator: Robert Colbert, MD, PhD – NIH/NIAMS
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    2:00 PM – 2:10 PM PT
    2437: Translocation of Intestinal Bacteria to Axial and Peripheral Joints in a Model of Spondyloarthropathy
    Location: Room 30D-E
    Presenting Author: Benjamin Cai, BS – The University of Queensland Frazer Institute
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    2:15 PM – 2:25 PM PT
    2438: Synovial Tissue Single-Cell Analysis Demonstrates Differential Fibroblast Populations Between RA and PsA Which Display Distinct Function
    Location: Room 30D-E
    Presenting Author: Órla Tynan, BSc (she/her/hers) – Molecular Rheumatology Department, Trinity College Dublin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    2:30 PM – 2:40 PM PT
    2439: Proteomic and Genomic Profiling of Plasma Exosomes from Ankylosing Spondylitis Patients
    Location: Room 30D-E
    Presenting Author: Fataneh Tavasolian, PhD – Krembil Research Institute - the University Health Network
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    2:45 PM – 2:55 PM PT
    2440: Synovial Shaping of Skin-derived Migrating Immune Cells Determines Initiation of Inflammation in Psoriatic Arthritis
    Location: Room 30D-E
    Presenting Author: Maria Gabriella Raimondo, MD – Uniklinikum Erlangen, Department of Medicine 3, Rheumatology and Immunology
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    3:00 PM – 3:10 PM PT
    2441: Upregulation of RANKL in the Skin of Patients with Psoriatic Arthritis
    Location: Room 30D-E
    Presenting Author: Maria de la Luz Garcia-Hernandez, PhD – University of Rochester
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    3:15 PM – 3:25 PM PT
    2442: Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis
    Location: Room 30D-E
    Presenting Author: Hillary Struthers, MS (she/her/hers) – Oregon Health & Science University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    4:00 PM – 5:30 PM PT
    14T178: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment III: AxSpA (2545–2550)
    Location: Exhibit Hall A-B
    Abstract Moderator: Abin Puravath, MD, FACP, MHS – Johns Hopkins University
    Abstract Moderator: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    4:00 PM – 4:10 PM PT
    2545: Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study
    Location: Exhibit Hall A-B
    Presenting Author: Atul Deodhar, MD – Oregon Health & Science University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    4:15 PM – 4:25 PM PT
    2546: Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up
    Location: Exhibit Hall A-B
    Presenting Author: Carla Goncalves Schahin Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    4:30 PM – 4:40 PM PT
    2547: Characteristics of Difficult-To-Treat Axial Spondyloarthritis: Results of a Multicentric Retrospective Study
    Location: Exhibit Hall A-B
    Presenting Author: Cecile PHILIPPOTEAUX, MD, PharmD, MSc – University Hospital Center of Lille
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    4:45 PM – 4:55 PM PT
    2548: Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
    Location: Exhibit Hall A-B
    Presenting Author: Martin Rudwaleit, MD – Klinikum Bielefeld Rosenhoehe, Bielefeld University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    5:00 PM – 5:10 PM PT
    2549: Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT
    Location: Exhibit Hall A-B
    Presenting Author: Walter P. Maksymowych, MD – University of Alberta
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Tuesday, Nov 14th
    5:15 PM – 5:25 PM PT
    2550: The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis
    Location: Exhibit Hall A-B
    Presenting Author: Katie Bechman, PhD, MSc, MBChB – King's College London
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Wednesday, Nov 15th
    9:15 AM – 10:15 AM PT
    15W112: Getting Skin and Joint in the Game: Key Players in the Psoriatic Arthritis Microenvironment
    Location: Room 25A-B
    Moderator: M. Elaine Husni, MD, MPH – Cleveland Clinic
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME: 1 hours
  • Wednesday, Nov 15th
    9:15 AM – 9:30 AM PT
    Immune-Stromal Cell Interactions in the Psoriatic Arthritis Joint
    Location: Room 25A-B
    Speaker: Ursula Fearon, PhD (she/her/hers) – Trinity College Dublin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Wednesday, Nov 15th
    9:30 AM – 9:45 AM PT
    Role of the Microbiome in Psoriasis and Psoriatic Arthritis
    Location: Room 25A-B
    Speaker: Jose Scher, MD – New York University School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Wednesday, Nov 15th
    9:45 AM – 10:00 AM PT
    New Mouse Models in Psoriatic Arthritis
    Location: Room 25A-B
    Speaker: Christopher Ritchlin, MD, MPH – University of Rochester Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Wednesday, Nov 15th
    10:00 AM – 10:15 AM PT
    Q&A
    Location: Room 25A-B
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)